|1.||Finsterer, Josef: 5 articles (07/2015 - 10/2003)|
|2.||de Boer, Anthonius: 5 articles (04/2014 - 01/2008)|
|3.||Stöllberger, Claudia: 4 articles (01/2015 - 10/2003)|
|4.||Schmidt-Lucke, Caroline: 4 articles (01/2007 - 12/2003)|
|5.||Nixdorff, Uwe: 4 articles (01/2007 - 12/2003)|
|6.||Stellbrink, Christoph: 4 articles (01/2007 - 12/2003)|
|7.||Redekop, William K: 3 articles (04/2014 - 06/2013)|
|8.||Verhoef, Talitha I: 3 articles (04/2014 - 06/2013)|
|9.||Rosendaal, Frits R: 3 articles (12/2013 - 06/2002)|
|10.||Behr, Sigrid: 3 articles (05/2012 - 07/2010)|
01/01/2015 - "He was started on phenprocoumon due to atrial fibrillation and systolic dysfunction. "
06/01/2013 - "To investigate the cost-effectiveness of pharmacogenetic-guided phenprocoumon dosing versus standard anticoagulation care in Dutch patients with atrial fibrillation. "
06/01/2013 - "Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation."
01/19/2012 - "[Expanded arsenal in atrial fibrillation: bye-bye marcumar?]."
09/12/2003 - "For the past two years she had been taking phenprocoumon because she had atrial fibrillation. "
01/15/2012 - "In conclusion, oral anticoagulation with phenprocoumon represents a safe and effective treatment in clinically stable patients with obstructive thrombosis of bioprosthetic aortic valves, thus obviating repeat valve surgery or thrombolysis."
09/01/2012 - "In fresh thrombi, anticoagulation with phenprocoumon results in thrombus resolution in most patients."
01/15/2012 - "We therefore evaluated oral anticoagulation with phenprocoumon as an alternative treatment for obstructive thrombosis of bioprosthetic valves. "
01/01/2012 - "In April 2009, the computed tomography (CT) scan revealed a portassociated thrombosis with cava superior syndrome, despite treatment with phenprocoumon and an international normalized ratio (INR) of 3.75 at the time of the event. "
05/01/2006 - "There was one valve-related late death due to mitral valve thrombosis without phenprocoumon. "
01/01/2009 - "Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients."
01/01/2008 - "This observational evaluation was restricted to ischaemic stroke or TIA patients with AF who were started on Phenprocoumon treatment during in-hospital stay. "
10/01/2003 - "Because of the additional risk factors for stroke/embolism, phenprocoumon was begun. "
07/01/2001 - "The patient had been treated with phenprocoumon for 5 months in order to prevent thromboembolism after two strokes assumed to be due to an open foramen ovale and an aneurysmatic atrial septum. "
12/02/2010 - "[Rivaroxaban at least as effective as marcumar in stroke prevention]."
|4.||Body Weight (Weight, Body)
01/01/1984 - "The model presented here is based on a phenprocoumon (PPC) standard dose calculated per kg body weight by adapting it to experimentally obtained mean values of biological half-life (t1/2) and relative volume of distribution (Vrel) of PPC taken from the literature. "
04/01/1994 - "The pharmacokinetics of phenprocoumon was studied in 24 healthy volunteers between the ages of 23 and 28 years and a mean body weight of 72 kg by intraindividual comparison of the plasma level after i.v. and oral administration of 9 mg phenprocoumon (PPC) or by the evaluation of the total plasma clearance of PPC by simultaneous measurement of the urinary excretion and of the plasma concentration after the administration of 9 mg PPC. "
03/01/1976 - "The first one was the control group without any manipulation, the second received an one-stage X-irradiation with 2500 R SD directed to the tail tumor, the third was treated with an oral dose of Phenprocoumon which was added to the daily drinking quantity (0.1 mg/kg body weight), and the fourth group was given an one-stage X-irradiation together with the oral Phenprocoumon treatment. "
02/01/2009 - "Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study. "
05/01/2013 - "Data were analyzed simultaneously using NONMEM VII. The model confirmed CYP2C9 and VKORC1 variants as the major predictors of variability in phenprocoumon concentrations and effects, together with body weight, age, comedication with CYP3A modifiers (i.e. "
01/01/1984 - "The metabolic clearance of phenprocoumon via glucuronidation, is relatively unaffected during cirrhosis compared with antipyrine clearance via oxidation."
12/01/1996 - "In the present study, we evaluated the effect of phenprocoumon on shunt patency after TIPSS placement using Palmaz stents; 49 patients with Child's A and B cirrhosis, who underwent successful TIPSS placement were randomized into the treatment group (n = 24) who received phenprocoumon and a control group (n = 25). "
11/01/1990 - "Although non-A, non-B hepatitis was initially suspected, the final diagnosis of phenprocoumon (Marcoumar)-induced hepatitis progressing to cirrhosis was based on recurrence of jaundice after re-exposure to the drug, improvement after withdrawal and centrilobular necrosis with eosinophilic infiltration in the liver biopsy. "
|1.||Electric Countershock (Cardioversion)
|4.||Transjugular Intrahepatic Portasystemic Shunt